Press Release |
October 25, 2023
EISAI PRESENTS NEW LEQEMBI® (LECANEMAB-IRMB) INVESTIGATIONAL SUBCUTANEOUS FORMULATION INTERIM STUDY RESULTS AND CLINICAL IMPROVEMENT DATA IN EARLIER STAGES OF EARLY ALZHEIMER'S DISEASE FROM ADDITIONAL ANALYSES OF CLARITY AD AT THE CLINICAL TRIALS ON ALZHEIMER'S DISEASE (CTAD) CONFERENCE
OUR PATIENT FOCUS
Discover how we make real contributions to patients and their families while observing the highest level of integrity
Diseases aren't the only adversities people face. Learn about the ways we help patients and their families throughout their health journey.